Samuel Rotstein, MD, Ph.D., appointed as Scientific Advisor to Biovica

Uppsala, Sweden, May 22 2017. Samuel Rotstein has been appointed as Scientific Advisor to Biovica.

 

Dr Rotstein received his Ph.D at Karolinska Institutet and has worked as an oncologist for almost 40 years. He was previously Head of Department at the Oncology Clinic at Danderyd Hospital where he together with his colleagues built and managed a highly-appreciated breast cancer clinic. As one of Sweden’s leading oncologists, he was honored last year with the Swedish Breast Cancer Patient Advocacy Association’s (BRO) Award 2016. Samuel Rotstein is currently working as a physician at Radiumhemmet, Karolinska University Hospital.

 

In the role as Scientific Advisor to Biovica, Samuel Rotstein, will contribute with his experience & expertise and assist the company in its extensive clinical study program and in the development of the company’s products.

 

“We are very pleased to have Dr. Samuel Rotstein as Medical Advisor to Biovica and we are looking forward to our collaboration. His experience in oncology and in breast cancer will be very valuable for Biovica and our long-term objectives to assist patients. Our goal is through our technology contribute to best possible treatment for cancer patients”, says Anders Rylander, CEO Biovica.

 

“I’m looking forward to working with Biovica. As more cancer treatments becomes available and more individualized, greater demands arise for improved diagnostic tools and evaluation methods in order to give the patient the optimal treatment”, says Dr. Samuel Rotstein.

 

More information

Anders Rylander, CEO Biovica

Phone: +46 (0)18 444 48 35
E-mail: anders.rylander@biovica.com

 

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.

Read more: www.biovica.com

2017-10-23T22:44:50+00:00 May 22nd, 2017 14:00|News|